A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

clinical trial

Details

Instance of: clinical trial
Start time: 16 December 2020
End time: 8 November 2023
Main subject: neurofibromatoses
clinical trial phase: phase I clinical trial
maximum age: 99
minimum age: 3
number of participants: 32
research subject recruitment status: active, not recruiting
study type: interventional study
title: A Phase 1 Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Selumetinib, a Selective Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor, in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Nothing in the MetaHistoryBook collection references this item yet.